Melody Cobleigh to Biomarkers
This is a "connection" page, showing publications Melody Cobleigh has written about Biomarkers.
Connection Strength
0.050
-
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016 06; 27(6):1029-1034.
Score: 0.026
-
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111(6):1241-8.
Score: 0.024